MMP2 and neoplasm: Recent data have emerged showing that monoclonal antibodies specifically targeting eHSP90α inhibited tumor formation via blocking the interaction of eHSP90 with matrix metalloproteinase 2 (MMP2) and MMP9 (110, 111).